Epidarex Capital
Epidarex Capital is a private equity firm based in Bethesda, Maryland, established in 2010. It specializes in early-stage investments in life sciences, healthcare, and technology companies, with a focus on under-ventured markets in the United States and the United Kingdom. The firm aims to provide sector-specific financial backing to young companies, particularly spin-outs from leading research universities. Epidarex Capital's international team is composed of experienced professionals and is supported by a diverse group of investors, including universities, corporations, development agencies, and financial institutions. The firm manages multiple funds that target various sectors within life sciences, including pharmaceuticals, biotechnology, and health technology.
Caldan Therapeutics Ltd is a biotechnology company that originated as a spinout from the University of Glasgow and the University of Southern Denmark. The company focuses on the development of novel therapeutics that target free fatty acid receptors, which play a significant role in the pathophysiology of metabolic diseases, particularly Type 2 Diabetes (T2D). Through a collaboration between Professor Graeme Milligan and Professor Trond Ulven, Caldan Therapeutics aims to address various aspects of T2D, including insulin secretion, insulin sensitivity, and islet cell protection. In addition to T2D, there is potential for the company's therapeutics to be applied in treating other conditions such as non-alcoholic steatohepatitis and inflammatory diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.